

Table I. Demographic and clinicopathological data.

Clinicopathological data	Total	Completed	Discontinued	P-value
Number of patients	58	34	24	
Age (years)	63.4±8.0	61.4±8.4	66.3±6.5	0.02
Gender				
Male	43 (74.1%)	24 (70.6%)	19 (79.2%)	0.42
Female	15 (25.9%)	10 (29.4%)	5 (20.8%)	
Histological classification				
Intestinal	23 (39.7%)	12 (35.3%)	11 (45.8%)	0.52
Diffuse	32 (55.2%)	19 (55.9%)	13 (54.2%)	
Adenosquamous	2 (3.4%)	2 (5.9%)	0 (0.0%)	
Tumor depth				
T2	24 (41.4%)	15 (44.1%)	9 (37.5%)	0.83
T3	32 (55.2%)	18 (52.9%)	14 (58.3%)	
T4	2 (3.4%)	1 (2.9%)	1 (4.2%)	
Lymph node metastasis				
N0	10 (17.2%)	6 (17.6%)	4 (16.7%)	0.85
N1	27 (46.6%)	15 (44.1%)	12 (50.0%)	
N2	21 (36.2%)	13 (38.2%)	8 (33.3%)	
Stage				
II	25 (43.1%)	15 (44.1%)	10 (41.7%)	0.18
IIIA	18 (31.0%)	8 (23.5%)	10 (41.7%)	
IIIB	15 (25.9%)	11 (32.4%)	4 (16.7%)	
Type of gastrectomy				
Total	30 (51.7%)	20 (58.8%)	10 (41.7%)	0.24
Distal	28 (48.3%)	14 (41.2%)	14 (58.3%)	
Reconstruction				
Billroth I	22 (37.9%)	11 (32.4%)	11 (45.8%)	0.48
Billroth II	3 (5.2%)	2 (5.9%)	1 (4.2%)	
Roux en Y	33 (56.9%)	21 (61.8%)	12 (50.0%)	
Cholecystectomy				
Yes	24 (41.4%)	14 (41.2%)	10 (41.7%)	0.95
No	34 (58.6%)	19 (55.9%)	14 (58.3%)	
Splenectomy				
Yes	20 (34.5%)	12 (35.3%)	8 (33.3%)	0.81
No	38 (65.5%)	22 (64.7%)	16 (66.7%)	
Doctor in charge				
Junior (≤15 yrs)	25 (43.1%)	11 (32.4%)	14 (58.3%)	0.04
Senior (>15 yrs)	33 (56.9%)	23 (67.6%)	10 (41.7%)	
Total amount of S-1 (mg)	16495.4±8851.9	23146.7±3335.6	7350.0±4954.9	<0.0001

principle, if patients had hematological toxic effects of grade 3 or 4 or non-hematological toxic effects of \geq grade 2, their daily dose was reduced and/or their schedule was changed from a 4-week administration followed by a 2-week rest, to a 2-week administration followed by a 1-week rest.

Measures. If no gross residual disease was evident at the time of surgery and the resection margins were tumor-free on histological examination, surgery was considered curative. Pathological findings in gastric cancer patients were described

on the basis of the JCGC (6). Adverse reactions were evaluated according to the common toxicity criteria of the National Cancer Institute, version 3.0 (<http://ctep.cancer.gov>).

OS was measured from the date of resection to the date of mortality from any cause. Relapse-free survival was measured from the date of resection to the date when relapse was evident by computed tomography, gastrointestinal endoscopic examination, abdominal ultrasonography, upper gastrointestinal series and/or positron emission tomography. Data for the patients who survived were censored in our survival analyses.

Table II. Adverse reactions to adjuvant therapy with S-1 among the 58 patients included in this study.

Adverse reaction	No. of patients				Percentage (%)	
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1 or 2	Grade 3 or 4
Leukopenia	5	3	3	-	14.0	5.3
Anemia	26	3	-	-	50.9	0
Elevated t-bil level	4	2	-	-	10.5	0
Stomatitis	5	2	-	-	12.3	0
Anorexia	20	1	1	-	36.8	1.8
Nausea	6	2	-	-	14.0	0
Diarrhea	8	6	1	-	24.1	1.8
Skin lesions	8	1	-	-	15.5	0
Fatigue	8	3	-	-	19.3	0
Watering or dry eye	7	6	-	-	22.8	0

t-bil, total bilirubin.

The medication completion rate was measured from the date of treatment commencement to the date of treatment discontinuation. Data for patients in whom S-1 treatment was discontinued due to tumor recurrence or mortality were censored in this analysis. All patients were observed at our hospital or outpatient clinic at 2- to 4-week intervals up to 12 months after surgery, 3- to 4-month intervals during the 2 years of the study and every 6 or 12 months thereafter for 3 years.

Statistical analysis. Statistical calculations were performed using StatView version 5.0 (SAS Institute, Inc., Cary, NC, USA). Data are expressed as the means \pm SEM. Statistical analyses were performed using the Mann-Whitney U test or Chi-square test with Fisher's exact test, as appropriate. Survival and medication completion rates were calculated using the Kaplan-Meier method and the significance of the difference was determined by a log-rank test. $P < 0.05$ was considered to indicate a statistically significant result.

Results

Of the 64 patients included in the study, 6 refused adjuvant therapy with S-1 due to age ($n=4$) or financial concerns ($n=2$). The remaining 58 patients received S-1 within 8 weeks of surgery (Fig. 1). Twenty-four patients (41.3%) discontinued treatment within 12 months as a result of disease relapse ($n=8$) and intolerable adverse events ($n=16$). The S-1 dose was decreased in 9 of the 58 patients (15.5%). Of the 34 patients who underwent treatment for 12 months, the S-1 dose was decreased in 6 (17.6%), and of the 24 patients who discontinued treatment, the S-1 dose was decreased in 3 (12.5%). Among the 58 patients who received S-1 therapy, treatment was continued for at least 3 months in 49 patients (84.5%), at least 6 months in 45 patients (77.6%), at least 9 months in 37 patients (63.8%) and 12 months in 34 patients (58.6%).

Demographic and clinicopathological data of patients are shown in Table I. Patients who discontinued S-1 treatment within 12 months were older than those who completed 12 months of adjuvant therapy. However, no differences were




Figure 1. Flowchart of the treatment outcomes of adjuvant therapy with S-1.

observed in tumor stage and surgery type (gastrectomy, reconstruction or resection of other organs) between the two groups. Patients who completed 12 months of adjuvant therapy with S-1 were more frequently treated by senior doctors (>15 years of experience). More favorable outcomes in OS and relapse-free survival were observed in these patients than in those who discontinued treatment (Fig. 2).

Table II summarizes the data concerning the adverse reactions observed among the 58 patients in this study. No patient had \geq grade 4 adverse events; however, 3 patients had grade 3 leukopenia. In terms of non-hematological adverse events, grade 3 anorexia was observed in 1 patient and grade 3 diarrhea was observed in 1 patient. The most frequent cause of S-1 treatment discontinuation was tumor recurrence. Non-hematological adverse events such as diarrhea and nausea were also associated with treatment discontinuation (Table III). Fig. 3 shows the medication completion rates. S-1 treatment time was significantly shorter in patients who




Figure 2. Overall and relapse-free survival rates following curative D2 gastric dissection. Completed, patients who completed 12 months of adjuvant therapy with S-1; Discontinuation, patients who discontinued treatment before 12 months.




Figure 3. Medication completion rates of adjuvant therapy with S-1 calculated by the Kaplan-Meier method. Discontinuation of S-1 administration due to adverse events was considered as an event.

experienced fatigue or nausea as an adverse event, whereas diarrhea and hematological toxicity did not significantly affect the period of treatment.

Discussion

This study demonstrated that patients who completed 12 months of adjuvant therapy with S-1 were younger and more frequently treated by doctors with >15 years of experience than those who did not. Non-hematological adverse events such as nausea and fatigue were frequent causes of S-1 treatment discontinuation. Adverse events of ≥ grade 3 were significant causes of treatment discontinuation in a small number of patients.

In a postmarketing survey of S-1 (9), including 3,294 patients with advanced or recurrent gastric cancer, the incidence of adverse reactions following administration of the drug at the usual dose level according to the patient body surface area was 74.1%, which was approximately equal to that obtained in

Table III. Chief causes of S-1 treatment discontinuation.

Adverse reaction	No. of patients	Percentage (%)
Recurrence	8	33.3
Diarrhea	3	12.5
Nausea	3	12.5
Elevated t-bil level	2	8.3
Intestinal obstruction	2	8.3
Fatigue	2	8.3
Neutropenia	1	4.2
Ascites	1	4.2
Stroke	1	4.2
Death of another cause	1	4.2
Total	24	100.0

t-bil, total bilirubin.

premarketing trials. The major reasons for drug discontinuation during the first and second course of therapy were exacerbation of symptoms (43%) and adverse drug reactions (33%). Therefore, to facilitate S-1 administration for prolonged time periods, the incidence of adverse reactions should be reduced. To accomplish this goal, several regimens have been established (10). Kimura *et al* developed a new S-1 dosing regimen in which S-1 is administered for a 2-week period separated by 1-week drug-free intervals, as adverse reactions due to S-1 therapy begin to appear 2-3 weeks after initial dosing (11). Sakuma *et al* also proposed alternate-day treatment with S-1 as a strategy for reducing toxicity, although the total dose of this regimen was 75% that of standard treatment (12). Both regimens decreased the incidence of adverse reactions and improved treatment compliance when compared with the conventional 4-week administration followed by a 2-week rest regimen.

In the ACTS-GC trial, 143 of 517 (27.7%) patients discontinued S-1 treatment due to adverse events, which was consistent with our results (27.6%). Only 5% patients in the ACTS-GC trial had metastasis or relapse of gastric cancer. Our study, which includes potentially more cases of advanced

stage disease than the ACTS-GC trial, involved relatively shorter time periods of the treatment than the ACTS-GC trial.

Patients who experienced fatigue or nausea as adverse events continued S-1 treatment for significantly shorter time periods. However, diarrhea and hematological toxicity did not significantly affect the treatment period. Following gastrectomy, fatigue and gastrointestinal symptoms such as nausea and appetite loss, even of \leq grade 2, appeared to have a major impact on treatment compliance.

In conclusion, the completion rate of S-1 treatment did not depend on the type of surgical procedures, i.e., gastrectomy, reconstruction or resection of other organs. Fatigue and gastrointestinal symptoms affected the period of treatment continuation. In addition, patients who completed 12 months of adjuvant therapy with S-1 were more frequently treated by doctors with ≥ 15 years of experience. Thus, to facilitate the continuation of adjuvant therapy with S-1, patients and doctors must be made completely aware of the issues of toxicity, compliance and efficacy associated with this therapy.

References

1. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, *et al*: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. *Cancer Res* 56: 2602-2606, 1996.
2. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. *Jpn J Cancer Res* 78: 748-755, 1987.
3. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. *Cancer Res* 53: 4004-4009, 1993.
4. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* 34: 1715-1720, 1998.
5. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. *Oncology* 58: 191-197, 2000.
6. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. *Gastric Cancer* 1: 10-24, 1998.
7. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, *et al*: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 357: 1810-1820, 2007.
8. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 14: 113-123, 2011.
9. Kawai H, Ohtsu A, Boku N, Hamamoto Y, Nagashima F, Muto M, *et al*: Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. *Gastric Cancer* 6: 19-23, 2003.
10. Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, *et al*: Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. *Gastric Cancer* 14: 28-34, 2011.
11. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, *et al*: A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. *Gastric Cancer* 6: 34-39, 2003.
12. Sakuma K, Hosoya Y, Arai W, Haruta H, Ui T, Kurashina K, *et al*: Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. *Int J Clin Oncol* 15: 166-171, 2010.

Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection

Yoshihiro Kakeji · Manabu Yamamoto · Shuhei Ito · Masahiko Sugiyama · Akinori Egashira · Hiroshi Saeki · Masaru Morita · Yoshihisa Sakaguchi · Yasushi Toh · Yoshihiko Maehara

Received: 13 January 2011 / Accepted: 7 April 2011 / Published online: 14 January 2012
© Springer 2012

Abstract

Purpose Both squamous cell carcinomas and adenocarcinomas can develop in the esophagogastric junction. To clarify the appropriate lymph node dissection range, lymph node metastases from cancers in the esophagogastric junction were investigated.

Methods The nodal metastases were analyzed in 64 patients with squamous cell carcinoma and 129 with adenocarcinoma according to Siewert's classification, which is based on topographic anatomical criteria for adenocarcinoma.

Results The squamous cell carcinomas located above the esophagocardial junction had more frequent metastasis to the lower and middle mediastinal lymph nodes in proportion to the depth of the tumor. Nodal metastasis was also often detected in the abdominal lymph nodes. In contrast, adenocarcinomas metastasized less frequently to the mediastinal lymph nodes, and the metastatic rates in the abdominal nodes were higher than those from squamous cell carcinoma.

Conclusion Esophagectomy with mediastinal and abdominal lymph node dissection is considered to be an appropriate approach for surgical resection of squamous cell carcinomas, whereas transhiatally extended gastrectomy with lower mediastinal and abdominal lymph node dissection is recommended for the treatment of adenocarcinomas.

Keywords Esophagogastric junction · Squamous cell carcinoma · Adenocarcinoma · Lymph node metastasis

Introduction

Cancer in the esophagogastric junction is an important clinical entity, as pathologically different tumors arise in this border between the esophageal squamous epithelium and the gastric adenomatous epithelium. The correct diagnosis of malignancy in this area is essential for choosing the appropriate surgical approach and for performing a resection that will provide the best patient outcome. In 2008, 406,806 people died from esophageal cancer worldwide, and 738,069 died from gastric cancer, making these the sixth and the second highest mortalities from cancer in the world [1]. Esophageal cancer is also one of the most aggressive cancers, with a 5-year survival rate of $25.0 \pm 0.6\%$ [2].

The incidence of adenocarcinoma of the esophagus and esophagogastric junction is dramatically increasing in Western countries [3, 4]. However, there is no evidence indicating a similar increase of adenocarcinoma of the esophagogastric junction in Eastern countries [5, 6]. Given their different pathogenic processes, epidemiology, tumor biology, and prognosis, squamous cell carcinomas and adenocarcinomas should be analyzed and reported separately [7–9]. Stein et al. [10] investigated early esophageal cancer, and reported that the prevalence and pattern of lymphatic spread, as well as the long-term prognosis, differ markedly between early esophageal squamous cell and adenocarcinoma. They recommended limited resection techniques and individualized lymphadenectomy strategies for patients with early adenocarcinoma.

Y. Kakeji (✉) · M. Yamamoto · A. Egashira · M. Morita · Y. Maehara

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan
e-mail: kakeji@surg2.med.kyushu-u.ac.jp

S. Ito · M. Sugiyama · H. Saeki · Y. Sakaguchi · Y. Toh
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan

There have not been any recent clinical studies on the pattern of lymphatic spread between squamous cell carcinoma and adenocarcinoma in the esophagogastric junction. With regard to squamous cell carcinoma of the lower esophagus, adding cervical lymph node dissection (3-field dissection) has been reported to provide a better survival benefit for patients compared to 2-field dissection [11]. In addition, adenocarcinoma of the gastric cardia or the upper part of the stomach has been reported to have a poorer prognosis than carcinomas of the more distal stomach [12, 13].


To improve patient survival, surgical resection, including complete removal of the primary tumor, together with its lymphatic drainage, is the mainstay of treatment for esophagogastric junction tumors [14]. To establish a more effective surgical treatment, the incidence of nodal metastasis from squamous cell carcinoma or adenocarcinoma of the esophagogastric junction was investigated in this study.

Patients and methods

A total of 193 patients with esophagogastric cancer who underwent surgery at the Department of Surgery and Science, Kyushu University Hospital and the Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan, from 1980 to 2005, were included in the study. Resected specimens were all examined pathologically and lymph node metastases were mapped.

The location of the primary cancer was classified using Siewert's classification, which is based on topographic-anatomical criteria for adenocarcinoma [15]. Adenocarcinoma of the esophagogastric junction was defined as tumors whose center was within 5 cm oral and aboral of the anatomical esophagogastric junction. Type I disease was defined as a tumor in which the center was located 1–5 cm above the esophagogastric junction (EGJ), regardless of invasion to the EGJ; type II was defined as a tumor invading the EGJ, in which the center was located between 1 cm above and 2 cm below the EGJ; and type III was defined as a tumor invading the EGJ, in which the center was located 2–5 cm below the EGJ (Fig. 1). This classification has been introduced from a surgical viewpoint, and approved at the consensus conference of the International Gastric Cancer Association (IGCA) and the International Society for Diseases of the Esophagus (ISDE) [16]. Although this classification is for adenocarcinoma, we also applied it to squamous cell carcinoma in this study to clarify the relationship between the anatomical location of the tumor and nodal metastasis.

The surgical approaches and nodal dissections performed are listed in Table 1. All 64 squamous cell carcinoma patients underwent the thoracoabdominal approach



Siewert JR, et al.: Dis Esophagus, 1996

Fig. 1 The Siewert classification. Topographic-anatomic classification of adenocarcinomas of the esophago-gastric junction (AEG) based on their relationship to the endoscopic gastric cardia. *Type I* Adenocarcinoma of the distal esophagus, *Type II* true adenocarcinoma of the cardia, *Type III* subcardial gastric carcinoma infiltrating the esophagogastric junction

with 59 two-field lymph node dissections (mediastinal and abdominal lymphadenectomy) and 5 three-field dissections (cervical, mediastinal, and abdominal lymphadenectomy) [17]. For adenocarcinoma, 30 patients underwent the thoracoabdominal approach, while 99 patients underwent the abdominal approach. The lymph node metastatic rates were calculated as the ratio between metastasis positive cases and the number of assessed cases in each numbered regional lymph node. The clinicopathological factors were evaluated according to the guidelines for clinical and pathologic studies on carcinoma of the esophagus [18, 19], and the Japanese classification of gastric carcinoma [20]. The recurrence pattern was investigated in 160 patients who underwent R0 resection, a microscopically margin-negative resection, in which no gross or microscopic tumor remained in the primary tumor bed. Survival data from 178 patients were analyzed by the Kaplan–Meier method.

Results

Of the 64 patients with squamous cell carcinoma, 41 patients had type I tumors and 23 patients had type II tumors. Of the 129 patients with adenocarcinoma, 6 patients had type I tumors, 60 patients had type II tumors, and 63 patients had type III tumors.

Squamous cell carcinoma


The metastatic rates in each lymph node are shown in Fig. 2. The rate of metastasis to Group 1 lymph nodes (1, 2, 3) was 16–28%. The metastatic rates to lower and middle mediastinal lymph nodes, which were Group 2 and 3 nodes, were 5–13 and 8%, respectively. Mediastinal lymph

Table 1 Surgical approaches and nodal dissections performed

Histology	No. of pts.	Approach	Lymph node dissection	No. of pts
Squamous cell carcinoma	64	Thoracoabdominal	3-field dissection	5
			2-field dissection	59
Adenocarcinoma	129	Thoracoabdominal	3-field dissection	3
			2-field dissection	27
		Abdominal	1-field dissection	99

Fig. 2 Metastatic rates of lymph nodes from squamous cell carcinoma. Cervical lymph nodes: 101, 102, 103, 104; upper mediastinal nodes: 105, 106; middle mediastinal nodes: 107, 108, 109

Squamous cell carcinoma n=64	
Lymph node	Metastatic rate (%)
cervical	3
upper mediastinal	2
middle mediastinal	8
110	13
111	5
112	5
1	28
2	16
3	16
4	2
5	0
6	2
7	16
8	2
9	5
10	2
11	5



nodes should therefore be dissected for patients with squamous cell carcinoma of the esophagogastric junction. Figure 3 shows the metastatic rates according to Siewert's classification. Compared to type I tumors, type II tumors had no upper mediastinal lymph node metastasis and more abdominal node metastasis. We experienced one type I and one type II tumor with cervical lymph node metastasis. These patients died 88 and 126 days postoperatively.

We also investigated the nodal metastatic rate in relation to the depth of tumor invasion (Table 2). Type I tumors, in which the tumor was located above the esophagocardial junction, had more metastasis to the lower and middle mediastinal lymph nodes in proportion to the depth of the tumor. Three pT1 tumors had no mediastinal node metastasis; however, one tumor had abdominal node metastasis. With regard to the type II tumors, which were located in the esophagocardial junction, mediastinal lymph node metastasis was not observed in pT1 and pT2 tumors, but was noted in patients with pT3 tumors. The nodal metastasis was often detected in the abdominal lymph nodes.

The recurrence pattern in relation to the depth of the tumor invasion is shown in Table 3. There was a higher

incidence of recurrence in the patients who had more invasive tumors. Lymph node metastasis occurred most frequently, followed by distant metastasis and local recurrence. The patients' survival is shown in Fig. 4. The prognoses of the patients with invasion to the esophageal adventitia (pT3) or to the adjacent organs (pT4) were poor.

Adenocarcinoma

Figure 5 shows the nodal metastatic rates from adenocarcinomas. Limited metastasis was observed in the mediastinal lymph nodes, and the metastatic rates in the abdominal nodes were higher than those from patients with squamous cell carcinoma. Figure 6 shows the metastatic rates according to Siewert's classification. In the six type I tumors, only one tumor had mediastinal lymph node metastasis, with a poor prognosis of 214 postoperative days. The abdominal lymph node metastasis was localized around the primary tumor. Type II and III tumors had higher metastatic rates in the abdominal lymph nodes than type I tumors. Although the prognosis of the single case with cervical or upper mediastinal lymph node metastasis

Fig. 3 The incidence of lymph node metastasis from squamous cell carcinoma according to the location of the tumor




Table 2 Lymph node metastasis from squamous cell carcinoma in relation to the depth of the tumor invasion

Depth of the tumor	Lymph node																				
	104	105	106	107	108	109	110	111	112	1	2	3	4	5	6	7	8	9	10	11	
Type I																					
pT1 (n = 3)	0	0	0	0	0	0	0	0	0	0	0	33	33	0	33	33	0	0	0	0	
pT2 (n = 6)	0	0	0	0	0	0	17	0	0	17	17	0	0	0	0	17	0	0	0	0	
pT3 (n = 27)	4	4	0	4	8	0	11	0	8	33	11	15	0	0	0	11	4	4	0	0	
pT4 (n = 5)	0	0	0	20	40	0	20	20	0	40	0	20	0	0	0	40	2	0	20	0	
Type II																					
pT1 (n = 1)	0	0	0	0	0	0	0	0	0	0	50	0	0	0	0	0	0	0	0	0	
pT2 (n = 2)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	50	0	0	0	0	
pT3 (n = 17)	6	0	0	0	6	0	18	12	6	35	29	24	0	0	0	12	0	12	0	18	
pT4 (n = 3)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

The number shows the metastatic rate (%)

Table 3 The recurrence pattern of squamous cell carcinoma in relation to the depth of the invasion of the tumor

Location	Depth	Number of cases	Recurrence (%)	Site of recurrence			
				Lymph node metastasis	Distant metastasis	Local recurrence	Peritoneal dissemination
Type I: 1–5 cm above the EGJ	pT1	3	0 (0)	0	0	0	0
	pT2	6	2 (33)	0	2	0	0
	pT3	24	13 (54)	7	3	2	0
	pT4	5	5 (100)	1	3	2	0
Type II: Between 1 cm above and 2 cm below the EGJ	pT1	1	0 (0)	0	0	0	0
	pT2	2	0 (0)	0	0	0	0
	pT3	9	6 (67)	3	2	1	0
	pT4	3	2 (67)	1	0	0	1

Fig. 4 The survival of patients with squamous cell carcinoma in relation to the depth of the tumor invasion





Fig. 5 The metastatic rates of lymph nodes from adenocarcinoma. Cervical lymph nodes: 101, 102, 103, 104; upper mediastinal nodes: 105, 106; middle mediastinal nodes: 107, 108, 109

Adenocarcinoma n=129	
Lymph node	Metastatic rate (%)
cervical	1
upper mediastinal	2
middle mediastinal	2
110	2
111	1
112	1
1	46
2	24
3	40
4	14
5	7
6	7
7	23
8	12
9	15
10	7
11	16
12	2
14	2
16	2



was poor (270 postoperative days), the prognosis of some cases with middle or lower mediastinal nodes was favorable after lymph node dissection (960, 1,099, 1,528 postoperative days). However, the cases with metastasis in the lymph nodes around the abdominal aorta had a poor prognosis (35, 331, 204, 294 postoperative days).

Figure 7 shows the mediastinal lymph node metastasis from adenocarcinoma in relation to the extent of the esophageal invasion. These data were from 23 patients who all underwent thoracotomy. Invasion into the esophagus by more than 1 cm was related to an increased incidence of mediastinal node metastasis. However, we did not find any evidence suggesting that there was any increase in nodal metastasis associated with a deeper esophageal invasion.

The cases with cervical lymph node metastasis (n4) had a poor prognosis, with the two patients dying on postoperative days 273 and 270. However, even the cases with more than 5 cm esophageal invasion survived for a relatively long time (960 and 1,528 postoperative days) after the combined resection of the lower esophagus and a mediastinal lymph node dissection.

The histology of the adenocarcinomas and lymph node metastases is shown in Table 4. Both differentiated and undifferentiated adenocarcinoma metastasized less frequently to the mediastinal lymph nodes than squamous cell carcinoma. With regard to the abdominal lymph nodes, undifferentiated adenocarcinomas metastasized more often than did the differentiated adenocarcinomas.

Fig. 6 The incidence of lymph node metastasis from adenocarcinoma according to the location of the tumor





Fig. 7 The incidence of lymph node metastasis from adenocarcinoma according to the extent of the esophageal invasion

The recurrence pattern in relation to the depth of tumor invasion is shown in Table 5. We found similar patterns for adenocarcinomas as were observed for the squamous cell carcinomas, in that the deeper the tumor invaded, the higher the incidence of recurrence the patients had. However, the major recurrence pattern was shifted from lymph node metastasis in Siewert’s type I cases to peritoneal dissemination in type III cases. Distant metastasis and local recurrence were also observed. The patients’ survival is shown in Fig. 8. The prognoses of the patients with tumor penetration of the serosa (pT3) or tumor invasion to adjacent structures (pT4) were poor. In patients with Siewert type III tumors, the survival of the patients with tumor invasion of the muscularis propria or subserosa (pT2) was also poor.

Discussion

Because an increase of cancer in the esophagogastric junction has been observed, and is expected to continue

increasing, the classifications of esophageal cancer and gastric cancer in this area have been harmonized in the East [21] and West [22]. In the Western world, most esophageal tumors are adenocarcinomas arising from the lower esophagus and the gastroesophageal junction [23]. In contrast, in Japan, squamous cell carcinoma represents more than 90% of all esophageal cancer cases [24].

The present study analyzed the incidence of lymph node metastases according to the location of the tumor. In patients with squamous cell carcinoma of the distal esophagus (Type I), the most common metastatic sites were the lower mediastinal and perigastric nodes. Although true cardia squamous cell carcinoma (Type II) tended to metastasize more frequently to the perigastric lymph nodes than Type I tumors did, it seemed to be appropriate to treat squamous cell carcinoma of the esophagogastric junction in accordance with the guidelines for thoracic esophageal cancer. The thoracoabdominal approach with two-field lymph node dissection is feasible for squamous cell carcinoma of the esophagogastric junction.

We seldom see cases of distal esophageal adenocarcinoma (Type I) in Japan, and the metastatic rates to the mediastinal lymph nodes of such patients were relatively low. Patients with true cardia adenocarcinomas (Type II) harbor metastases in lymph nodes of the paracardial region, lesser and greater curvatures, left gastric artery toward the celiac axis, splenic artery, superior border of the pancreas toward the splenic hilum, and the lower posterior mediastinum [13, 25]. Total gastrectomy with a transhiatal resection of the distal esophagus may be the best approach for these Type II tumors [10]. Subcardiac adenocarcinomas (Type III) more frequently metastasize to intraabdominal lymph nodes. Extended surgery, such as a retroperitoneal

Table 4 Lymph node metastasis from adenocarcinoma in relation to the histology

Histology	Mediastinal lymph node									
	104	105	106	107	108	109	110	111	112	
Differentiated (<i>n</i> = 83)	1	1	0	1	2	0	2	0	0	
Undifferentiated (<i>n</i> = 44)	0	0	0	0	0	0	2	2	2	


Histology	Abdominal lymph node													
	1	2	3	4	5	6	7	8	9	10	11	12	14	16
Differentiated (<i>n</i> = 83)	43	20	36	8	4	5	22	7	11	4	13	1	0	1
Undifferentiated (<i>n</i> = 44)	50	34	48	25	14	11	27	20	23	14	20	5	7	5

The number shows the metastatic rate (%)

Table 5 The recurrence pattern of adenocarcinoma in relation to the depth of the tumor invasion

Siewert's classification location	Depth	Number of cases	Recurrence (%)	Site of recurrence			
				Lymph node metastasis	Distant metastasis	Local recurrence	Peritoneal dissemination
Type I: 1–5 cm above the EGJ	pT1	1	0 (0)	0	0	0	0
	pT2	2	1 (50)	1	0	0	0
	pT3	2	1 (50)	1	0	0	0
Type II: Between 1 cm above and 2 cm below the EGJ	pT1	9	0 (0)	0	0	0	0
	pT2	12	5 (42)	3	0	2	0
	pT3	29	20 (69)	4	8	5	6
	pT4	2	2 (100)	1	1	1	0
Type III: 2–5 cm below the EGJ	pT1	7	0 (0)	0	0	0	0
	pT2	12	6 (50)	4	3	0	2
	pT3	18	13 (72)	1	6	0	9
	pT4	13	9 (69)	0	0	1	9

Fig. 8 The survival of patients with adenocarcinoma in relation to the depth of the tumor invasion



lymphadenectomy with left-sided pancreatic resection plus splenectomy, has not been recommended because of its negative side-effects [26, 27].

For patients with highly advanced pT3 or pT4 tumors, standard surgery alone does not exert an effect sufficient to improve the patient survival. Most of these cases had recurrences, distant metastasis, or peritoneal dissemination. It does not seem to be necessary to perform more extended resection or dissection for esophagogastric cancer [14]. In addition, the value of neoadjuvant chemotherapy has not been established as a standard therapy. Therefore, not only for patients with local lymphatic recurrence but also for patients with distant hematogenous recurrence, it is important to define the subset(s) of patients who might benefit from neoadjuvant chemotherapy. Accurately predicting chemosensitivity based on either the molecular characteristics or the use of diagnostic imaging devices should be therefore the focus of future studies.

In conclusion, based on the present data about squamous cell carcinoma, a transthoracic esophagectomy with two-field lymphadenectomy appears to be feasible, and for adenocarcinoma, a total gastrectomy with transhiatal distal esophagectomy is recommended unless lymph node metastases have been detected in the proximal part of the chest.

References

- World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide in 2008. <http://globocan.iarc.fr/> (accessed on November 28, 2010).
- Tsukuma H, Ajiki W, Ioka A, Oshima A, Research Group of Population-Based Cancer Registry of Japan. Survival of cancer patients diagnosed in 1993–96: collaborative study of population-based cancer registries in Japan. *Jpn J Clin Oncol*. 2006;36:602–7.
- Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer*. 1998;83:2049–53.
- Pohl H, Welch G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. *J Natl Cancer Inst*. 2005;97:142–6.
- Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. *Surgery*. 2008;143:499–508.
- Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. *Gastric Cancer*. 2010;13:63–73.
- Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? *Semin Rad Oncol*. 2006;17:38–44.
- Natsugoe S, Aikou T, Yoshinaka H, Saihara T, Baba M, Takao S, et al. Lymph node metastasis of early stage carcinoma of the esophagus and of the stomach. *J Clin Gastroenterol*. 1995;20:325–8.
- Ohdaira H, Nimura H, Takahashi N, Mitsumori N, Kashiwagi H, Narimiya N, et al. The possibility of performing a limited resection and a lymphadenectomy for proximal gastric carcinoma based on sentinel node navigation. *Surg Today*. 2009;39:1026–31.
- Stein HJ, Feith M, Bruecher BLDM, Naehrig J, Sarbia M, Siewert JR. Early esophageal cancer. Pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. *Ann Surg*. 2005;242:566–75.
- Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-Field dissection. *Ann Surg*. 2004;239:483–90.
- Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, Sugimachi K. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. *J Am Coll Surg*. 1995;180:577–82.
- Yamamoto M, Baba H, Egashira A, Oki E, Ikebe M, Kakeji Y, Maehara Y. Adenocarcinoma of the esophagogastric junction in Japan. *Hepatogastroenterology*. 2008;55:103–7.
- von Rahden BH, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. *World J Gastroenterol*. 2006;12:6608–13.
- Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. *Dis Esophagus*. 1996;9:173–82.
- Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg*. 1998;85:1457–9.
- Sannohe Y, Hiratsuka R, Doki K. Lymph node metastases in cancer of the thoracic esophagus. *Am J Surg*. 1981;141:216–8.
- Japanese Society for Esophageal Disease. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. *Esophagus*. 2004;1:61–88.
- Japanese Society for Esophageal Disease. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part II. *Esophagus*. 2004;1:107–25.
- Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (The 13th Japanese edition). 2nd English ed. *Gastric Cancer* 1998;1:10–24.
- Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (in Japanese). 14th ed. Tokyo: Kanehara-shuppan; 2010.
- Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Tritti A, editors. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2009.
- Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. *J Surg Oncol*. 2005;92:151–9.
- Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. *Ann Surg*. 2000;232:225–32.
- Siewert JR, Stein HJ, von Rahden BH. Multimodal treatment of gastrointestinal tract tumors: consequences for surgery. *World J Surg*. 2005;29:940–8.
- Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T, Kito T. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. *World J Surg*. 1997;21:622–7.
- Kitamura K, Nishida S, Ichikawa D, Taniguchi H, Hagiwara A, Yamaguchi T, Sawai K. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. *Br J Surg*. 1999;86:119–22.

Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery

Toshiro Okuyama · Daisuke Korenaga · Ai Edagawa · Shinji Itoh · Eiji Oki · Hirofumi Kawanaka · Yasuharu Ikeda · Yoshihiro Kakeji · Masahiro Tateishi · Shunichi Tsujitani · Kenji Takenaka · Yoshihiko Maehara

Received: 25 March 2011 / Accepted: 22 June 2011 / Published online: 27 January 2012
© Springer 2012

Abstract

Purpose We conducted this retrospective study to evaluate the effectiveness of giving oral anti-cancer drugs for 2 years as postoperative adjuvant chemotherapy to gastric cancer patients.

Methods The subjects were 76 patients with stage II and III gastric cancer, who underwent curative surgery between 1989 and 2008. We divided the 20 years chronologically into the UFT term (1989–2003) and the S-1 term (2004–2008). The patients from each term were then divided into three groups according to the length of drug administration; namely, the surgery alone group, the 1-year group, and the 2-year group.

Results The survival time of the 2-year group was better than that of the surgery alone group, not only in the UFT term, but also in the S-1 term ($P = 0.0224$). Longer relapse-free survival was evident in the S-1 term, especially for the 2-year group ($P = 0.0110$). A multivariate analysis showed both the stage of the cancer and 2 years of postoperative adjuvant chemotherapy to be independent factors predictive of prolonged survival ($P = 0.0040$ and $P = 0.0022$, respectively).

Conclusions The 2-year administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy might improve the outcome of stage II, III gastric cancer patients.

Randomized control trials are warranted to prove the effectiveness of this 2-year regimen.

Keywords Gastric cancer · Adjuvant chemotherapy · Two years administration · Oral anti-cancer drugs

Introduction

Postoperative adjuvant chemotherapy is commonly given after the curative resection of gastric cancer in both Eastern and Western countries [1–4]. Two recent randomized trials on postoperative adjuvant chemotherapy showed significant survival benefits of gastrectomy followed by UFT [5-fluorouracil (5-FU) analog, tegafur combined with uracil in a ratio of 1:4, Taiho Pharmaceutical Co. Ltd., Tokyo, Japan], and S-1 (a new oral fluoropyrimidine containing tegafur, 5-chloro-2, 4-dihydropyrimidine and potassium oxonate, Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) versus surgery alone [5, 6]. Several meta-analyses also support the effectiveness of adjuvant therapy [7–9].

These findings suggest the efficacy of adjuvant chemotherapy using a tegafur-based regimen for curatively resected gastric cancer with extensive lymph node dissection [10, 11]. However, the optimal length of time for which these drugs should be administered has not been established.

Several studies have evaluated the effects of giving chemotherapy for periods ranging from 6 to 12 months [12]; however, Kodama et al. [13] proposed a 2-year regimen of postoperative long-term combination chemotherapy (PLCC) for curatively resected gastric cancer after observing a better prognosis in these patients. Based on the strategy of PLCC, some patients at our institute have been treated with oral anti-cancer drugs for 2 years or longer postoperatively, and have been followed up long-term under close surveillance.

T. Okuyama (✉) · D. Korenaga · A. Edagawa · S. Itoh · H. Kawanaka · Y. Ikeda · M. Tateishi · K. Takenaka
Department of Surgery, Fukuoka City Hospital,
13-1 Yoshizuka-honmachi, Hakata-ku,
Fukuoka 812-0046, Japan
e-mail: okuyama929@yahoo.co.jp

E. Oki · Y. Kakeji · S. Tsujitani · Y. Maehara
Department of Surgery and Science, Graduate School of Medical
Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan

We conducted this study to compare the effectiveness of 1 versus 2 years of UFT or S-1 as postoperative adjuvant chemotherapy for stage II or III gastric cancer. The data were examined by both univariate and multivariate analyses.

Patients and methods

Patients

The subjects of this study were 76 patients with primary gastric cancer pathologically classified as stage II or III, who underwent surgery in Fukuoka City Hospital between 1989 and 2008. The patients were selected based on the following criteria: they were younger than 80 years old, they had no double cancer history, and the cause of death was limited to the original diseases. None of the patients had received neoadjuvant chemotherapy.

The mean age of the patients was 62.2 ± 11.1 years (range 33–79 years old) and there were 50 men and 26 women. The 76 patients were chronologically divided into the UFT term group (1989–2003, $n = 47$) and the S-1 term group (2004–2007, $n = 29$) according to the drugs administered postoperatively. The UFT group included those treated with conventional tegafur-based drugs, mainly UFT. After having taken the drugs for 1 year, the patients in each group were informed of the expected advantages and disadvantages of continuing to take the drugs for a second year. When the patients agreed to the concept of long-term adjuvant chemotherapy, the drugs were administered for an additional year. We compared the prognoses of patients treated with surgery alone, those treated with 1 year of adjuvant chemotherapy, and those treated with 2 years of adjuvant chemotherapy.

Clinicopathological investigation

We assessed the clinicopathological factors according to the Japanese Classification of Gastric Carcinoma outlined by the Japanese Gastric Cancer Association [14].

Table 1 Drug dosages and lengths of administration in each term

Term	UFT term ($n = 47$)			S-1 term ($n = 29$)		
	1989–2003			2004–2008		
Years						
Groups	Surgery alone ($n = 11$)	1-year UFT treatment ($n = 27$)	2-years UFT treatment ($n = 9$)	Surgery alone ($n = 10$)	1-year S1 treatment ($n = 6$)	2-years S-1 treatment ($n = 13$)
Dosage of drugs (mg/day)	–	361 ± 112	333 ± 132	–	92.0 ± 17.9	100 ± 14.8
Length of administration (months)	–	10.4 ± 3.0	23.1 ± 5.6	–	12.3 ± 3.7	25.2 ± 3.4

Follow-up

Patient follow-up continued until death and only those patients who died of gastric cancer were included in the analysis. The postoperative follow-up period ranged from 221 to 5760 days (mean 1581 ± 1293 , median 1223.5 days).

Adverse effects of the drugs

Adverse reactions of the drugs in each regimen were monitored and evaluated at the outpatient clinic, based on the criteria of Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Statistical Analysis

Both univariate and multivariate analyses were conducted to establish the association between prognosis and age, sex, depth of tumor invasion, lymph node metastasis, and adjuvant chemotherapy in the 1- and 2-year UFT and S-1 groups. Statistical analyses were performed among the groups, using the Chi-square or non parametric Wilcoxon tests or the Cochran–Armitage trend test. Survival curves were generated by the Kaplan–Meier method and the log-rank test was used to analyze the equality of the survival curves. A Cox proportional hazard model was used for the multivariate analyses to determine the independent prognostic factors. A P value of less than 0.05 was considered to indicate significance.

Results

Profiles of the patients in each term

Table 1 shows the daily drug dosages and the length of their administration in the UFT group (1989–2003) and the S-1 group (2004–2008). Table 2 summarizes the clinical findings in the surgery alone, 1-year, and 2-year treatment groups within the UFT group. Although there were no

Table 2 Background of the patients in the UFT term (1989–2003)

Factors	Surgery alone (<i>n</i> = 11)	UFT 1 year (<i>n</i> = 27)	UFT 2 years (<i>n</i> = 9)	<i>p</i> value
Age ^a	67.8 ± 7.7	61.7 ± 12.8	60.6 ± 11.9	0.113
Male vs. female	7 vs. 4	18 vs. 9	5 vs. 4	0.744
Depth of tumor invasion				
t1,2	5 (45.5%)	14 (51.9%)	2 (22.2%)	0.355
t3,4	6 (54.5%)	13 (48.1%)	7 (77.8%)	
Extent of lymph node metastasis				
n0,1	2 (18.2%)	10 (37.0%)	7 (77.8%)	0.009
n2,3	9 (81.8%)	17 (63.0%)	2 (22.2%)	
Histological type				
Undifferentiated	4 (36.4%)	14 (51.9%)	6 (66.7%)	0.1756
Differentiated	7 (63.6%)	13 (48.1%)	3 (33.3%)	
Stage				
II	1 (9.1%)	6 (27.3%)	2 (22.2%)	0.669
IIIA	8 (72.3%)	15 (45.4%)	4 (44.4%)	
IIIB	2 (18.6%)	6 (27.3%)	3 (33.4%)	
Lymph node dissection				
D0,1	1 (9.1%)	3 (11.1%)	0 (%)	0.474
D2,3	10 (90.9%)	24 (88.9%)	10 (100%)	

^a Mean ± standard deviation**Table 3** Background of the patients in the S-1 term (2004–2008)

Factors	Surgery alone (<i>n</i> = 10)	S-1, 1 year (<i>n</i> = 6)	S-1, 2 years (<i>n</i> = 13)	<i>p</i> value
Age ^a	63.6 ± 10.3	62.2 ± 5.4	58.0 ± 13.6	0.273
Male vs. female	5 vs. 5	5 vs. 1	10 vs. 3	0.196
Depth of tumor invasion				
t1,2	7 (70.0%)	2 (33.3%)	6 (46.2%)	0.303
t3,4	3 (30.0%)	4 (66.7%)	7 (54.8%)	
Extent of lymph node metastasis				
n0,1	8 (80.0%)	2 (33.3%)	6 (46.2%)	0.136
n2,3	2 (20.0%)	4 (66.7%)	7 (54.8%)	
Histological type				
Undifferentiated	6 (60.0%)	1 (16.7%)	6 (46.2%)	0.617
Differentiated	4 (40.0%)	5 (83.3%)	7 (54.8%)	
Stage				
II	6 (60.0%)	2 (33.3%)	4 (30.8%)	0.125
IIIA	3 (30.0%)	2 (33.3%)	5 (38.4%)	
IIIB	1 (10.0%)	2 (33.3%)	4 (30.8%)	
Lymph nodes dissection				
D0,1	0 (0%)	0 (0%)	0 (0%)	1.000
D2,3	14 (100%)	6 (100%)	13 (100%)	

^a Mean ± standard deviation

significant differences in age, sex, depth of tumor invasion, stage, or lymph node dissection, there was a significantly lower incidence of extensive lymph node metastasis in the 2-year group than in the other two groups ($P = 0.009$). Table 3 summarizes the clinical findings of the patients in the S-1 group, which showed no significant difference in backgrounds.

Survival rates

There were no significant differences in 5-year survival rates between either of the UFT-treatment groups and the patients treated with surgery alone in this term ($P = 0.0617$, Fig. 1a). Conversely, the 5-year survival rate of all the patients treated with S-1 was significantly better than




Fig. 1 Survival curves of the patients in the UFT (1989–2003) and S-1 (2004–2008) terms. **a** The dotted line represents the surgery alone group ($n = 11$) and the heavy line represents both the UFT groups ($n = 36$). There was no significant difference between the groups. **b** The dotted line represents the surgery alone group ($n = 10$) and the heavy line represents both the S-1 groups ($n = 19$). The P value was 0.0303, indicating significance

that of the patients treated with surgery alone in this term ($P = 0.0303$, Fig. 1b). Survival curves according to the time each drug administered for are shown in Fig. 2. Survival of the 2-year UFT-treated patients was significantly better than that of the surgery alone group in this term ($P = 0.0286$, Fig. 2a). Similarly, survival of the 2-year S-1-treated patients was significantly better than that of the surgery alone group in this term ($P = 0.0224$, Fig. 2b). Ultimately, S-1 administration resulted in significantly better relapse-free survival in all patients ($P = 0.0108$, Fig. 3a). There was a significant difference in relapse-free survival time between the surgery alone group and the 2-year S-1 treated group ($P = 0.0110$, Fig. 3b).

Univariate and multivariate analyses were conducted for each pathologic factor (Table 4). The multivariate analysis proved that stage and 2 years of postoperative adjuvant chemotherapy were independent factors for prolonged survival ($P = 0.0400$ and $P = 0.0022$, respectively).




Fig. 2 Survival curves according to whether adjuvant therapy was given for 1 year or 2 years postoperatively. **a** The dotted line represents the surgery alone group ($n = 11$), the light line represents the 1-year UFT-treatment group ($n = 27$) and the heavy line represents the 2-year UFT-treatment group ($n = 9$). The P value was 0.0286, indicating significance. **b** The dotted line represents the surgery alone group ($n = 10$), the light line represents the 1-year S-1 treatment group ($n = 6$) and the heavy line represents the 2-year S-1 treatment group ($n = 13$). The P value was 0.0224, indicating significance

Adverse reactions

Table 5 summarizes the adverse reactions observed during all treatment courses in the S-1 group according to CTCAE version 4.0. Two grade 2 cases were recognized in the 1-year S-1 group and one grade 2 case was recognized in the 2-year S-1 group. Myelosuppressive, mucositis, and gastrointestinal toxicities were generally mild and there was no treatment-related death. The dosage was decreased by 20% for one patient with grade 2 leukopenia. No adverse reactions of more than grade 3 toxicity occurred in any group.

Recurrence

Table 6 summarizes the sites of recurrence and the second-line chemotherapy in the S-1 group. The sites of recurrence were distributed in various organs of the hosts. Second-line




Fig. 3 Progression-free survival curves in the S-1 term. **a** The dotted line represents the surgery alone group ($n = 10$) and the heavy line represents both the UFT groups ($n = 19$). The P value was 0.0108, indicating significance. **b** The dotted line represents the surgery alone group ($n = 10$), the light line represents the 1-year UFT group ($n = 6$) and the heavy line represents the 2-year UFT group ($n = 13$). The P value was 0.0110, indicating significance

chemotherapy usually comprised either the single or combined use of taxane, cisplatin, and S-1.

Discussion

The purpose of adjuvant chemotherapy is to eradicate residual cancer cells in the peritoneal cavity after curative surgery [15]. The main mechanisms are recognized as better perfusion of blood, allowing access of the drug to small tumor cells; and better sensitivity to most anticancer drugs in cells with a higher rate of rapid proliferation in small tumors [16, 17].

The cytotoxicity of 5-FU is dose- and time-dependent with its accumulation in the blood [18]. Better survival rates are observed in patients given a higher dose of UFT after curative surgery for gastric cancer [19]. Kodama et al. [13] advocated the concept of the PLCC for resected gastric cancer, with a regimen of 2 years of oral mitomycin C, tegafur (oral 5-FU analog) and immunostimulator,

Table 4 Univariate and multivariate analyses of the prognostic factors over the whole study period

Factors	Univariate analysis p value	Multivariate analysis		
		p value	Hazard ratio	95% CI
Age				
<65 vs. >65 years	0.3877	0.3871	1.3606	0.6771–2.7342
Sex				
Male vs. female	0.4347	0.4356	0.7425	0.3512–1.5696
Depth of tumor invasion				
t1,2 vs. t3,4	0.5556	0.5548	1.2417	0.6054–2.5468
Lymph node metastasis				
n0,1 vs. n2,3	0.1151	0.1200	1.8189	0.8557–3.8663
Histological type				
undifferentiated vs. differentiated	0.7315	0.7311	0.8831	0.4346–1.7944
Stage				
II vs. IIIA, IIIB	0.0320	0.0400	3.0544	1.0523–8.8712
Lymph nodes dissection				
D0,1 vs. D2,3	0.9332	0.9331	1.0633	0.2536–4.4583
Period of adjuvant chemotherapy				
none vs. 1 year	0.0769	0.0799	0.5168	0.2469–1.0818
none vs. 2 years	0.0004	0.0022	0.1397	0.0396–0.4928

CI confidence interval

Table 5 The adverse reactions observed during all treatment courses in the S-1 group according to CTCAE Ver. 4.0

Toxicity	S-1 groups	
	1 year ($n = 6$)	2 years ($n = 13$)
Grade 2		
Leukopenia	0 (0%)	1 (7.7%)
Neutropenia	0 (0%)	0 (0%)
Anemia	0 (0%)	0 (0%)
Thrombocytopenia	0 (0%)	0 (0%)
Anorexia	1 (16.7%)	0 (0%)
Diarrhea	0 (0%)	0 (0%)
Nausea/vomiting	0 (0%)	0 (0%)
Mucositis	1 (16.7%)	0 (0%)
Pigmentation	0 (0%)	0 (0%)
Grade 3	0 (0%)	0 (0%)

after observing that it achieved a better prognosis. Similar findings were observed in patients with stage IV gastric cancer and esophageal cancer after esophagectomy [20, 21].

Maehara et al. [22] reported that S-1 is the standard first-line postoperative adjuvant chemotherapy for resected

Table 6 Sites of recurrence and the second-line regimens in the S-1 group

Term	S-1 term (<i>n</i> = 29)		
	Surgery alone (<i>n</i> = 10)	1 year (<i>n</i> = 6)	2 years (<i>n</i> = 13)
Cases of recurrence	6 (60.0%)	3 (50.0%)	2 (15.4%)
Recurrence site			
Liver	0	1	0
Anastomotic site	0	0	1
Peritoneum	2	1	1
Lymphnodes	3	0	0
Lung	0	1	0
Bone	1	0	0
Second-line regimen			
Taxane	1	1	1
LV + 5FU	0	1	0
S-1 + taxane	1	0	1
S-1 + cisplatin	1	0	0

LV leucovorin

gastric cancer, in accordance with the current recommendation of the 1-year administration of S-1 as the standard postoperative adjuvant chemotherapy regimen for stage II and III gastric cancer [6, 23]. In the present series, the oral anti-cancer dose- and time-dependent drugs, UFT and S-1, were administered for up to 2 years or longer, based on the PLCC strategy to improve prognosis. The patients were followed up carefully in the outpatient clinic under close surveillance for compliance and adverse reactions, because cytotoxic 5-FU could accumulate in their bodies [18].

Previous data reveal that PLCC courses are occasionally suspended following adverse effects, such as bone marrow suppression, serious gastrointestinal manifestations, and liver dysfunction, but recommenced thereafter on the completion of adequate treatments [13, 20]. The adverse effects after 2 years administration in the present series were also mild, demonstrating the feasibility of this 2-year adjuvant chemotherapy regimen.

This study found a favorable prognosis for increased overall survival in the 2-year UFT and S-1 groups and increased relapse-free survival in the 2-year S-1 group. Furthermore, multivariate analyses revealed the prognostic significance of giving the adjuvant therapy drugs for 2 versus 1 year. These findings are consistent with those of the previous PLCC studies [13, 20, 21], supporting the 2-year administration of these cancer drugs. The administration of S-1 might not be recommended for very elderly patients, because of the risk of severe adverse reactions. UFT might be preferred for older patients because of its mild toxicity [24].

In conclusion, the findings of the present study suggest that the 2-year administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy may lead to a favorable outcome for stage II and III gastric cancer patients. However, no definitive conclusions can be drawn until randomized control trials are conducted to prove the effectiveness of this 2-year regimen.

Conflict of interest Toshiro Okuyama and his co-authors have no conflict of interest.

References

- Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. *Br J Cancer*. 1992;65:413–6.
- Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. *Lancet*. 1999;354:273–7.
- Macdonald J, Smalley SR, Benedetti J, Hundahl SA, Norman C, Estes NC, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med*. 2001;345:725–30.
- Costanzo FD, Gasperoni S, Manzione L, Bisagni G, Lbianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. *J Natl Cancer*. 2008;100:388–98.
- Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. *Br J Surg*. 2007;94:1468–76.
- Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, ACTS-GC Group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med*. 2008;357:1810–20.
- Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. *J clin oncology*. 1993;11:1441–7.
- Pignon JP, Ducreux M, P Rougier. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. *J clin oncol*. 1994;12:877–8.
- Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: A study of the GISCAD. *Ann Oncol*. 2000;11:837–43.
- Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. *Int J Clin Oncol*. 2009;14:85–9.
- Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. *Surg Today*. 2010;40:295–300.
- Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: a comprehensive review. *Gastric Cancer*. 2001;4:175–84.
- Kodama Y, Kano T, Tamada R, Kumashiro R, Okamura T, Inokuchi K. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach. *Surg Today*. 1982;12:244–8.

14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. *Gastric Cancer* 1998; 1:10–24.
15. Ringborg U. Adjuvant chemotherapy—a discussion of some basic principles. *Acta Oncol.* 1991;30:251–3.
16. Tannock I. Adjuvant chemotherapy—basic science. *The basic science of oncology.* 2004. p. 356–7.
17. Epstein RJ. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. *Clin Cancer Res.* 2005;11:5337–41.
18. Hanaue H, Kurosawa T, Kitano Y, Miyakawa S, Nemoto A, et al. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. *Cancer.* 1987;59:1571–6.
19. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. *Cancer Chemother Pharmacol.* 1997;40:233–8.
20. Kaibara N, Soejima K, Nakamura T, Inokuchi K. Postoperative long term cancer chemotherapy for advanced gastric cancer. *Surg Today.* 1976;6:54–9.
21. Okudaira Y, Sugimachi K, Inokuchi K, Kai H, Kuwano H, Matsuura H. Postoperative long term immunochemotherapy for esophageal carcinoma—5 year survival. *Surg Today.* 1982;12: 249–56.
22. Maehara Y. S-1 in gastric cancer: a comprehensive review. *Gastric Cancer.* 2003;6:2–8.
23. Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. 3rd edn. Japan: Japanese Gastric Cancer Association; 2010. p. 26–27 (in Japanese).
24. Tanaka F. UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. *Surg Today.* 2007;37: 923–43.

A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer

Kazuhiro Nishikawa · Satoshi Morita · Takanori Matsui · Michiya Kobayashi · Yoji Takeuchi · Ikuo Takahashi · Seiji Sato · Yumi Miyashita · Akira Tsuburaya · Junichi Sakamoto · Yoshihiro Kakeji · Hideo Baba

Received: 27 July 2011 / Accepted: 26 November 2011 / Published online: 26 January 2012
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2012

Abstract

Background The purpose of this study was twofold: (1) to compare S-1 with infusional 5-fluorouracil (FU) to determine which would be a better partner of paclitaxel (PTX), and (2) to compare a concurrent strategy with a sequential one, the latter strategy being the one that is widely used in Japanese general practice.

Methods The 161 eligible patients were randomized into four arms to receive the following regimens: A (sequential), intravenous 5-FU at 800 mg/m² for 5 days

every 4 weeks followed by weekly PTX at 80 mg/m²; B (sequential), S-1 at 80 mg/m² for 4 weeks and 2-week rest followed by PTX; C (concurrent), intravenous 5-FU at 600 mg/m² for 5 days and weekly PTX at 80 mg/m² every 4 weeks; and D (concurrent), S-1 for 14 days and PTX at 50 mg/m² on days 1 and 8 every 3 weeks. The primary endpoint was the overall survival (OS) rate at 10 months.

Results The ten-month OS rates in arms A, B, C, and D were 63, 65, 61, and 73%, respectively. The OS was best in the concurrent S-1/PTX arm, with a mean survival time of

K. Nishikawa (✉)
Department of Surgery, Osaka General Medical Center,
3-1-56 Bandai-higashi, Sumiyoshi-ku, Osaka 558-8558, Japan
e-mail: kazuno1@gh.opho.jp

S. Morita
Department of Biostatistics and Epidemiology,
Yokohama City University, 4-57 Urafune-cho, Minami-ku,
Yokohama 232-0024, Japan

T. Matsui
Department of Gastroenterological Surgery,
Aichi Cancer Center, Aichi Hospital, 18 Kuriyado,
Kakemachi, Okazaki 444-0011, Japan

M. Kobayashi
Department of Human Health and Medical Sciences,
Kochi Medical School, Kohasu-Okochi, Nankoku,
Kochi 783-8505, Japan

Y. Takeuchi
Department of Gastrointestinal Oncology, Osaka Medical Center
for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi,
Higashinari-ku, Osaka 537-8511, Japan

I. Takahashi
Department of Surgery, Matsuyama Red Cross Hospital,
1 Bunkiyomachi, Matsuyama, Ehime 790-8524, Japan

S. Sato
Department of Surgery, Saga Prefectural Hospital Koseikan,
1-12-9 Mizugae, Saga 840-8571, Japan

Y. Miyashita
Epidemiological and Clinical Research Information Network,
21-7 Shogoin, Sanno-cho, Sakyo-ku, Kyoto 606-8392, Japan

A. Tsuburaya
Department of Surgery, Kanagawa Cancer Center, 1-1-2 Nakao,
Asahi-ku, Yokohama 241-0851, Japan

J. Sakamoto
Department of Young Leaders' Program in Health Care
Administration, Nagoya University Graduate School of
Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Y. Kakeji
Department of Surgery and Science, Graduate School of Medical
Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan

H. Baba
Department of Gastroenterological Surgery, Graduate School of
Medical Sciences, Kumamoto University, 1-1-1 Honjo,
Kumamoto 860-8556, Japan